CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Clinical Studies
Original article

NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

Phase 2NEO100Positive
AI Analysis

Summary

NeOnc Technologies will host an investor conference call on August 12, 2026, to discuss topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma.

Clinical Trial Data

Phase

2a

Outcome Details

Topline Phase 2a results to be discussed

Importance:6/10
Sentiment:
0.30
Phase 2CNSGliomaIntranasalData readout
Related Companies
$NTHI

Read the original article

Published by GlobeNewswire Clinical Studies on August 10, 2026 12:30 PM

Read Original